These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 20042499)

  • 1. Effect of mutations in the human immunodeficiency virus type 1 protease on cleavage of the gp41 cytoplasmic tail.
    Waheed AA; Ablan SD; Sowder RC; Roser JD; Schaffner CP; Chertova E; Freed EO
    J Virol; 2010 Mar; 84(6):3121-6. PubMed ID: 20042499
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HIV-1 escape from the entry-inhibiting effects of a cholesterol-binding compound via cleavage of gp41 by the viral protease.
    Waheed AA; Ablan SD; Roser JD; Sowder RC; Schaffner CP; Chertova E; Freed EO
    Proc Natl Acad Sci U S A; 2007 May; 104(20):8467-71. PubMed ID: 17483482
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of HIV-1 replication by amphotericin B methyl ester: selection for resistant variants.
    Waheed AA; Ablan SD; Mankowski MK; Cummins JE; Ptak RG; Schaffner CP; Freed EO
    J Biol Chem; 2006 Sep; 281(39):28699-711. PubMed ID: 16882663
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV-1 protease, Gag and gp41 baseline substitutions associated with virological response to a PI-based regimen.
    Perrier M; Castain L; Regad L; Todesco E; Landman R; Visseaux B; Yazdanpanah Y; Rodriguez C; Joly V; Calvez V; Marcelin AG; Descamps D; Charpentier C
    J Antimicrob Chemother; 2019 Jun; 74(6):1679-1692. PubMed ID: 30768160
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New mechanisms of resistance in virological failure to protease inhibitors: selection of non-described protease, Gag and Gp41 mutations.
    Castain L; Perrier M; Charpentier C; Palich R; Desire N; Wirden M; Descamps D; Sayon S; Landman R; Valantin MA; Joly V; Peytavin G; Yazdanpanah Y; Katlama C; Calvez V; Marcelin AG; Todesco E
    J Antimicrob Chemother; 2019 Jul; 74(7):2019-2023. PubMed ID: 31050739
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interplay between single resistance-associated mutations in the HIV-1 protease and viral infectivity, protease activity, and inhibitor sensitivity.
    Henderson GJ; Lee SK; Irlbeck DM; Harris J; Kline M; Pollom E; Parkin N; Swanstrom R
    Antimicrob Agents Chemother; 2012 Feb; 56(2):623-33. PubMed ID: 22083488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulation of human immunodeficiency virus type 1 Env-mediated membrane fusion by viral protease activity.
    Murakami T; Ablan S; Freed EO; Tanaka Y
    J Virol; 2004 Jan; 78(2):1026-31. PubMed ID: 14694135
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gp41 and Gag amino acids linked to HIV-1 protease inhibitor-based second-line failure in HIV-1 subtype A from Western Kenya.
    Coetzer M; Ledingham L; Diero L; Kemboi E; Orido M; Kantor R
    J Int AIDS Soc; 2017 Nov; 20(3):. PubMed ID: 29098809
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Domains of the human immunodeficiency virus type 1 matrix and gp41 cytoplasmic tail required for envelope incorporation into virions.
    Freed EO; Martin MA
    J Virol; 1996 Jan; 70(1):341-51. PubMed ID: 8523546
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Maturation-dependent human immunodeficiency virus type 1 particle fusion requires a carboxyl-terminal region of the gp41 cytoplasmic tail.
    Jiang J; Aiken C
    J Virol; 2007 Sep; 81(18):9999-10008. PubMed ID: 17609279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cell-dependent requirement of human immunodeficiency virus type 1 gp41 cytoplasmic tail for Env incorporation into virions.
    Akari H; Fukumori T; Adachi A
    J Virol; 2000 May; 74(10):4891-3. PubMed ID: 10775630
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Coupling of human immunodeficiency virus type 1 fusion to virion maturation: a novel role of the gp41 cytoplasmic tail.
    Wyma DJ; Jiang J; Shi J; Zhou J; Lineberger JE; Miller MD; Aiken C
    J Virol; 2004 Apr; 78(7):3429-35. PubMed ID: 15016865
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of human immunodeficiency virus type 1 gp41 amino acid substitutions selected during enfuvirtide treatment on gp41 binding and antiviral potency of enfuvirtide in vitro.
    Mink M; Mosier SM; Janumpalli S; Davison D; Jin L; Melby T; Sista P; Erickson J; Lambert D; Stanfield-Oakley SA; Salgo M; Cammack N; Matthews T; Greenberg ML
    J Virol; 2005 Oct; 79(19):12447-54. PubMed ID: 16160172
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of human immunodeficiency virus type 1 resistance to protease inhibitors on evolution of resistance to the maturation inhibitor bevirimat (PA-457).
    Adamson CS; Waki K; Ablan SD; Salzwedel K; Freed EO
    J Virol; 2009 May; 83(10):4884-94. PubMed ID: 19279107
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of Transmitted Drug-Resistance Mutations and Polymorphisms in HIV-1 Reverse Transcriptase, Protease, and gp41 Sequences Among Recent Seroconverters in Southern Poland.
    Smoleń-Dzirba J; Rosińska M; Kruszyński P; Bratosiewicz-Wąsik J; Wojtyczka R; Janiec J; Szetela B; Beniowski M; Bociąga-Jasik M; Jabłonowska E; Wąsik TJ; The Cascade Collaboration In EuroCoord A
    Med Sci Monit; 2017 Feb; 23():682-694. PubMed ID: 28167814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Polar Region of the HIV-1 Envelope Protein Determines Viral Fusion and Infectivity by Stabilizing the gp120-gp41 Association.
    Lu W; Chen S; Yu J; Behrens R; Wiggins J; Sherer N; Liu SL; Xiong Y; Xiang SH; Wu L
    J Virol; 2019 Apr; 93(7):. PubMed ID: 30651369
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural studies on molecular mechanisms of Nelfinavir resistance caused by non-active site mutation V77I in HIV-1 protease.
    Gupta A; Jamal S; Goyal S; Jain R; Wahi D; Grover A
    BMC Bioinformatics; 2015; 16 Suppl 19(Suppl 19):S10. PubMed ID: 26695135
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanistic Analysis of the Broad Antiretroviral Resistance Conferred by HIV-1 Envelope Glycoprotein Mutations.
    Hikichi Y; Van Duyne R; Pham P; Groebner JL; Wiegand A; Mellors JW; Kearney MF; Freed EO
    mBio; 2021 Jan; 12(1):. PubMed ID: 33436439
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A cleavage enzyme-cytometric bead array provides biochemical profiling of resistance mutations in HIV-1 Gag and protease.
    Breuer S; Sepulveda H; Chen Y; Trotter J; Torbett BE
    Biochemistry; 2011 May; 50(20):4371-81. PubMed ID: 21452835
    [TBL] [Abstract][Full Text] [Related]  

  • 20. I36T↑T mutation in South African subtype C (C-SA) HIV-1 protease significantly alters protease-drug interactions.
    Maseko SB; Padayachee E; Govender T; Sayed Y; Kruger G; Maguire GEM; Lin J
    Biol Chem; 2017 Sep; 398(10):1109-1117. PubMed ID: 28525359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.